EI- Nile Co. for Pharmaceuticals and Chemical Industries (EGX:NIPH)
Egypt
· Delayed Price · Currency is EGP 98.89
+2.34 (2.42%)
At close: Mar 5, 2026
EGX:NIPH Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 1,849 | 1,290 | 1,143 | 1,005 | 876.78 | 755.51 | Upgrade
|
| Revenue Growth (YoY) | 108.78% | 12.86% | 13.66% | 14.65% | 16.05% | -7.02% | Upgrade
|
| Cost of Revenue | 1,265 | 881.75 | 890.14 | 733.17 | 654.21 | 554.43 | Upgrade
|
| Gross Profit | 584.38 | 407.83 | 252.44 | 272.05 | 222.57 | 201.08 | Upgrade
|
| Selling, General & Admin | 134.05 | 123.16 | 101.98 | 100.02 | 91.51 | 83.27 | Upgrade
|
| Other Operating Expenses | 1.24 | 5.34 | 6.94 | 9.27 | 5.63 | 22.21 | Upgrade
|
| Operating Expenses | 135.29 | 128.5 | 108.93 | 109.28 | 97.13 | 105.48 | Upgrade
|
| Operating Income | 449.09 | 279.33 | 143.52 | 162.76 | 125.44 | 95.6 | Upgrade
|
| Interest Expense | -103.75 | -70.21 | -25.32 | -13.72 | -3.18 | -3.67 | Upgrade
|
| Interest & Investment Income | 9.45 | 6.41 | 2.05 | 2.25 | 4.79 | 5.74 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.21 | 4.72 | 9.76 | 7.88 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -45.85 | -56.4 | -21.77 | -14.04 | -10.76 | -15.07 | Upgrade
|
| EBT Excluding Unusual Items | 313.15 | 163.86 | 108.24 | 145.13 | 116.3 | 82.6 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.31 | - | - | Upgrade
|
| Other Unusual Items | -0.73 | -0.62 | - | - | - | - | Upgrade
|
| Pretax Income | 312.42 | 163.23 | 108.24 | 145.44 | 116.3 | 82.6 | Upgrade
|
| Income Tax Expense | 68.43 | 37.5 | 18.01 | 26.22 | 26.63 | 18.18 | Upgrade
|
| Earnings From Continuing Operations | 243.99 | 125.73 | 90.23 | 119.21 | 89.67 | 64.42 | Upgrade
|
| Net Income | 243.99 | 125.73 | 90.23 | 119.21 | 89.67 | 64.42 | Upgrade
|
| Net Income to Common | 243.99 | 125.73 | 90.23 | 119.21 | 89.67 | 64.42 | Upgrade
|
| Net Income Growth | 889.95% | 39.35% | -24.32% | 32.94% | 39.20% | -31.01% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | 196.30% | 196.30% | - | - | - | - | Upgrade
|
| EPS (Basic) | 8.13 | 4.19 | 8.91 | 11.77 | 8.86 | 6.36 | Upgrade
|
| EPS (Diluted) | 8.13 | 4.19 | 8.91 | 11.77 | 8.86 | 6.36 | Upgrade
|
| EPS Growth | 234.11% | -52.97% | -24.32% | 32.94% | 39.20% | - | Upgrade
|
| Free Cash Flow | -576.6 | -472.96 | -155.57 | -284.07 | -43.83 | 75.09 | Upgrade
|
| Free Cash Flow Per Share | -19.22 | -15.77 | -15.37 | -28.06 | -4.33 | 7.42 | Upgrade
|
| Dividend Per Share | 2.000 | 2.000 | 3.710 | 5.000 | 2.970 | 2.000 | Upgrade
|
| Dividend Growth | -46.09% | -46.09% | -25.80% | 68.35% | 48.50% | - | Upgrade
|
| Gross Margin | 31.61% | 31.62% | 22.09% | 27.06% | 25.39% | 26.62% | Upgrade
|
| Operating Margin | 24.29% | 21.66% | 12.56% | 16.19% | 14.31% | 12.65% | Upgrade
|
| Profit Margin | 13.20% | 9.75% | 7.90% | 11.86% | 10.23% | 8.53% | Upgrade
|
| Free Cash Flow Margin | -31.18% | -36.68% | -13.62% | -28.26% | -5.00% | 9.94% | Upgrade
|
| EBITDA | 493.96 | 307.9 | 155.52 | 492.94 | 139.36 | 107.68 | Upgrade
|
| EBITDA Margin | 26.71% | 23.88% | 13.61% | 49.04% | 15.89% | 14.25% | Upgrade
|
| D&A For EBITDA | 44.87 | 28.57 | 12 | 330.18 | 13.91 | 12.08 | Upgrade
|
| EBIT | 449.09 | 279.33 | 143.52 | 162.76 | 125.44 | 95.6 | Upgrade
|
| EBIT Margin | 24.29% | 21.66% | 12.56% | 16.19% | 14.31% | 12.65% | Upgrade
|
| Effective Tax Rate | 21.90% | 22.98% | 16.64% | 18.03% | 22.89% | 22.01% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.